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The bacterium *Staphylococcus aureus* (*S. aureus*) was originally described in 1880 by Sir Alexander Ogston ([@bib9]). Since then, strains of *S. aureus* that are resistant to different antibiotics, first penicillin and then methicillin, began to emerge. Methicillin-resistant *S. aureus* (MRSA) is now endemic in many hospitals and is one of the leading causes of infections contracted in the healthcare setting ([@bib6]). Thus, there is a clear need to better understand the process of bacterial infection and especially how host cells respond to these potentially deadly threats. Mammalian organisms combat bacterial infections by rapidly inducing innate immune responses. In a recent issue of *Nature*, [@bib5] describe a previously unknown mechanism of innate immunity that involves the ability of cells to produce exosomes, a specific class of extracellular vesicles (EVs), that function as a protective barrier and prevent bacterial toxins from reaching their target cells.

Exosomes are small EVs, \~30--120 nm in diameter, that originate in the endo-lysosomal trafficking pathway as intraluminal vesicles within multivesicular bodies. They are released from cells when multivesicular bodies fuse with the plasma membrane. Microvesicles (MVs), which represent the second major class of EVs, are larger than exosomes (0.2--2.0 μm in diameter) and are derived as a result of their outward budding and release from the plasma membrane. Both exosomes and MVs engage and transfer their associated protein and nucleic acid cargo to other cells, thus altering the cells' behavior. This form of intercellular communication has been studied extensively in the context of cancer, where it has been shown that EVs shed by cancer cells interact with neighboring cancer cells as well as with non-cancerous cells that reside either locally within the tumor microenvironment or at distant sites. These interactions promote aggressive phenotypes including accelerated cell growth, therapy resistance, invasiveness, and metastasis ([@bib7]). Recently, exosomes released by melanoma cells have also been shown to engage and inactivate immune cells, thus enabling tumor cells to evade an immune response ([@bib1]).

The work described in [@bib5] now sheds new light on how EVs, and in particular exosomes, are produced by cells as a mechanism to protect against pathogenic agents by acting as cellular decoys. This discovery stemmed from earlier findings, which showed that mice and cells depleted of the autophagy-related protein 16-1 **(**ATG16L1) were far more susceptible to MRSA strains that release the pore-forming alpha-toxin compared to wild-type mice and cells ([@bib8]). [@bib5] then determined the mechanistic basis by which ATG16L1 mediated this effect, showing that it was dependent on changes in the expression level of the metalloprotease ADAM10. Alpha-toxin is known to bind ADAM10 when it is expressed on the surfaces of cells and to mediate the formation of pores. Interestingly, in cells lacking ATG16L1, the levels of ADAM10 detected on their plasma membranes was increased, which led to a corresponding increase in alpha-toxin-mediated pore formation and cell death. Since autophagy-related machinery has been demonstrated to regulate exosome biogenesis ([@bib4]), the authors suspected that ATG16L1 decreases the sensitivity of cells to MRSA by influencing the release of exosomes containing ADAM10. Indeed, cells expressing sufficient amounts of ATG16L1 were found to produce large quantities of exosomes containing the metalloprotease, while cells depleted of ATG16L1 released far fewer of these exosomes, leading to the idea that the shedding of greater numbers of exosomes containing ADAM10 creates a protective barrier surrounding the cells. Thus, alpha-toxins released by MRSA strains in the vicinity of a cell would more likely bind to an exosome, causing the toxins to undergo oligomerization and to become inactivated, thereby highlighting a form of innate immunity that was not previously appreciated.

The authors next examined whether the formation and release of exosomes containing ADAM10 might be increased when cells were treated with a variety of different bacteria ([@bib5]). The results from these experiments showed that *S. aureus*, as well as other pathogens, including *Streptococcus pneumoniae*, *Citrobacter rodentium*, and *Salmonella enterica*, were similarly capable of enhancing the production of exosomes, suggesting that the release of these EVs represents a general mechanism used by cells to reduce the infectivity of bacterial pathogens. The authors then carried out two additional *in vivo* experiments that greatly solidified their findings. In the first of these experiments, proteomic analysis was performed on exosomes that were isolated from plasma collected from MRSA-infected mice. The results elegantly show that most of the exosomes originated in the liver, a hotspot for MRSA infection ([@bib10]). In the second experiment, the authors wanted to see whether exosomes were protective *in vivo*. Exosomes isolated from the blood of donor mice treated with an attenuated form of *S. aureus* were injected into recipient mice that were being exposed to a lethal dose of the bacteria. While control animals rapidly died from the infection, animals that received exosome treatments lived significantly longer. When taken collectively, the results of this study suggest that injecting exosomes, or potentially even liposomes containing ADAM10 ([@bib2]), could provide a new strategy for combating bacterial infections and might offer an especially useful treatment for individuals with compromised immune systems or when antibiotic resistance develops.

In conclusion, the study by [@bib5] provides a striking and novel example of how exosomes can impact biological responses in surprising ways; in this case, by serving as decoy agents to protect host cells against bacterial pore-forming toxins ([Figure 1](#fig1){ref-type="fig"} ). These findings now join a growing list of examples in which exosomes, and EVs in general, either act to protect parental cells from which they are derived against incoming signals that otherwise would compromise cell survival or provide a mechanism for intercellular communication that confers cells with a biological advantage. In some cases, the actions of these vesicles have deleterious effects with regard to disease progression and pathological disorders. Included among such examples are the ability of exosomes shed by aggressive cancer cells to block immune surveillance and thus interfere with immune therapy ([@bib1]) and the actions of larger EVs (i.e., MVs) in stimulating VEGF receptors on endothelial cells and activating the initial stages of tumor angiogenesis in a manner that is insensitive to the anti-angiogenesis drug bevacizumab ([@bib3]). However, in other cases, like the study described here, they provide a beneficial effect to the health of the organism. There are likely to be many more instances of how EVs are used to provide a benefit or survival advantage to their parental cells. For example, in light of the striking challenges we are facing due to the COVID-19 outbreak, an intriguing question is whether cells might also use exosomes to mitigate viral infections. Given the ever-increasing appreciation of their biological significance, with both good and bad consequences, it will be critical to address fundamental questions regarding the biogenesis of exosomes and other EVs in specific cellular and biological contexts. It also will be increasingly important to design novel strategies to manipulate their production and shedding, either to increase their numbers when advantageous to good health or to inhibit their generation when it contributes to diseases such as metastatic cancer and neurodegenerative disorders.Figure 1ATG16L1-Expressing Cells Release Exosomes that Neutralize *S. aureus* Alpha-ToxinUpon exposure to *S. aureus*, ATG16L1-expressing cells release large amounts of exosomes that have the metalloprotease ADAM10 on their surfaces. The alpha-toxin released by *S. aureus* binds to these exosomes and becomes oligomerized and inactivated, providing a mechanism of innate immunity that effectively diminishes the virulence of pathogenic bacteria (i.e., MRSA).
